Johnson & Johnson (JNJ) Stake Raised by Merriman Wealth Management LLC

Merriman Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,258 shares of the company’s stock after acquiring an additional 996 shares during the quarter. Merriman Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,123,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Cornerstone Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after acquiring an additional 2,473,105 shares during the period. Bank of Montreal Can raised its holdings in shares of Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after acquiring an additional 1,833,622 shares during the period. Summit Trail Advisors LLC raised its holdings in shares of Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,752,841 shares during the period. Flossbach Von Storch AG grew its position in Johnson & Johnson by 53.3% during the second quarter. Flossbach Von Storch AG now owns 3,553,636 shares of the company’s stock valued at $431,198,000 after purchasing an additional 1,235,186 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado grew its position in Johnson & Johnson by 212.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock valued at $181,770,000 after purchasing an additional 1,019,002 shares in the last quarter. Institutional investors and hedge funds own 66.51% of the company’s stock.

JNJ stock opened at $145.43 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $391.46 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 2.28 and a beta of 0.59. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.90 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is 49.32%.

A number of research analysts recently commented on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Citigroup boosted their price objective on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Finally, Raymond James boosted their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $143.90.

In other Johnson & Johnson news, EVP Michael E. Sneed sold 30,943 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $142.46, for a total value of $4,408,139.78. Following the completion of the sale, the executive vice president now directly owns 70,817 shares of the company’s stock, valued at $10,088,589.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 166,695 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total transaction of $24,405,814.95. Following the completion of the sale, the vice president now directly owns 155,540 shares of the company’s stock, valued at $22,772,611.40. The disclosure for this sale can be found here. Insiders sold 510,544 shares of company stock valued at $74,414,877 over the last three months. Insiders own 0.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Raised by Merriman Wealth Management LLC” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/johnson-johnson-jnj-stake-raised-by-merriman-wealth-management-llc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading: Stop Order

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply